Top News
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Survival Outcomes Associated With Infusion Reactions With Rituximab in Diffuse Large B-Cell Lymphoma
No Influence of Measurable Residual Disease on Haploidentical Transplantation Outcomes in AML
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
ASCO Decision Aid Helps Physician-Investigators Attribute SAEs to a Drug
Novel Therapies on the Horizon for Waldenström Macroglobulinemia
Biosimilar Truxima Now Available for Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Hematologic Scoring System Predicts Survival in Multiple Myeloma
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response. -
Vaping Injuries Raise New Concerns About Medical Marijuana
Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana. -
ASCO Opinion Poll: Americans’ Knowledge About Cancer
The results of a recent ASCO poll suggest that many adults are unsure how to reduce their cancer risk and do not know what sources of information to trust. -
Nivolumab Plus Ipilimumab in Advanced Melanoma Improves Survival at 5-Year Follow-Up — but Significant Toxicities Linger
A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities. -
Ultrahypofractionated SBRT Prostate Cancer Radiotherapy Does Not Increase Radiotoxicities
Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B. -
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that. -
Assessing Novel Therapies in HIV-Positive Patients With Cancer
Evidence is emerging about the safety and efficacy of CAR-T therapy and CRISPR-based editing techniques in cancer patients with HIV. -
Why Cardiac Toxicity Should Not Prevent the Use of Ibrutinib for CLL or SLL
Final results of a landmark trial confirm the efficacy of ibrutinib for CLL and SLL—and while cardiovascular issues remain a concern, the benefits appear to outweigh the risks.
More Features
Tools for Assessing, Managing Elderly With Cancer for Malnutrition
This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Soluble PD-1 Is a Potential Biomarker in Metastatic Melanoma in Patients Treated With Autologous Vaccines
A small study on patients with metastatic melanoma who were treated with autologous vaccines in a phase 2 clinical trial suggests that soluble PD-1 may have potential as a prognostic biomarker.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
